Abstract
Cardiomyopathies are a heterogeneous group of primary diseases of the myocardium usually of genetic origin and with familial presentation. The identification of multiple genetic causes for these diseases has opened a new window for early diagnosis, understanding of their natural history and improvement in risk stratification and management. However, in the past years, the clinical application of genetics has been limited by the prohibiting cost and restricted yield of the available genotyping technologies. The emergence of Next Generation Sequencing (NGS) has completely changed this scenario. This group of sequencing technologies allow the evaluation of hundreds or even thousands of genes in parallel at an affordable cost. Now the challenge is not genotyping per se but the interpretation of the complex results that NGS generates. In this paper we review the main aspects related to the application and impact of Next Generation Sequencing in the study of cardiomyopathies: technology, analysis procedures, bioinformatics, clinical validation and interpretation of results.
Keywords: Cardiomyopathies, genetics, next generation sequencing.
Current Pharmaceutical Design
Title:Genetics of Cardiomyopathies: Novel Perspectives with Next Generation Sequencing
Volume: 21 Issue: 4
Author(s): Lorenzo Monserrat, Martin Ortiz-Genga, Ivan Lesende, Diego Garcia-Giustiniani, Roberto Barriales-Villa, David de Una-Iglesias, Petros Syrris and Alfonso Castro-Beiras
Affiliation:
Keywords: Cardiomyopathies, genetics, next generation sequencing.
Abstract: Cardiomyopathies are a heterogeneous group of primary diseases of the myocardium usually of genetic origin and with familial presentation. The identification of multiple genetic causes for these diseases has opened a new window for early diagnosis, understanding of their natural history and improvement in risk stratification and management. However, in the past years, the clinical application of genetics has been limited by the prohibiting cost and restricted yield of the available genotyping technologies. The emergence of Next Generation Sequencing (NGS) has completely changed this scenario. This group of sequencing technologies allow the evaluation of hundreds or even thousands of genes in parallel at an affordable cost. Now the challenge is not genotyping per se but the interpretation of the complex results that NGS generates. In this paper we review the main aspects related to the application and impact of Next Generation Sequencing in the study of cardiomyopathies: technology, analysis procedures, bioinformatics, clinical validation and interpretation of results.
Export Options
About this article
Cite this article as:
Monserrat Lorenzo, Ortiz-Genga Martin, Lesende Ivan, Garcia-Giustiniani Diego, Barriales-Villa Roberto, Una-Iglesias de David, Syrris Petros and Castro-Beiras Alfonso, Genetics of Cardiomyopathies: Novel Perspectives with Next Generation Sequencing, Current Pharmaceutical Design 2015; 21 (4) . https://dx.doi.org/10.2174/138161282104141204123748
DOI https://dx.doi.org/10.2174/138161282104141204123748 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Cardiac Disease
Recent Patents on Biomarkers Simultaneous Spectrophotometric Determination of Iron (III) and Vanadium (V) in Water Samples Using a Combination of Partial Least Squares Regression and Solid Phase Extraction with Modified Octadecyl Silica Membrane Disks
Current Analytical Chemistry Mitochondrial Dysfunction and Lipid Homeostasis
Current Drug Metabolism Protein O-GlcNAcylation: A Critical Regulator of the Cellular Response to Stress
Current Signal Transduction Therapy Pharmacological Approaches of Binge Drinking
Current Pharmaceutical Design Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Current Alzheimer Research Endothelial Expression of MHC Class II Molecules in Autoimmune Disease
Current Pharmaceutical Design Methods for Identifying Cardiovascular Agents: A Review
Recent Patents on Cardiovascular Drug Discovery Population Pharmacogenomics and Personalized Medicine Research in Hungary: Achievements and Lessons Learned
Current Pharmacogenomics and Personalized Medicine Cardiac Remodeling Induced by Smoking: Concepts, Relevance, and Potential Mechanisms
Inflammation & Allergy - Drug Targets (Discontinued) Risk Prediction Models and Scores in Hypertrophic Cardiomyopathy
Current Pharmaceutical Design Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Flavonoids in the Treatment of Diabetes: Clinical Outcomes and Mechanism to Ameliorate Blood Glucose Levels
Current Diabetes Reviews Heart Failure in East Asia
Current Cardiology Reviews Long-term Success and Follow-up After Atrial Fibrillation Ablation
Current Cardiology Reviews Improving Nutritional Quality of Plant Proteins Through Genetic Engineering
Current Genomics Use of Bromine-76 and Iodine-123 Radiohalogenated Tracers in the Drug Development Process
Current Pharmaceutical Design